JP7460551B2 - 抗ｈｅｒ２抗体 - Google Patents

抗ｈｅｒ２抗体 Download PDF

Info

Publication number
JP7460551B2
JP7460551B2 JP2020565255A JP2020565255A JP7460551B2 JP 7460551 B2 JP7460551 B2 JP 7460551B2 JP 2020565255 A JP2020565255 A JP 2020565255A JP 2020565255 A JP2020565255 A JP 2020565255A JP 7460551 B2 JP7460551 B2 JP 7460551B2
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
amino acid
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020565255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513368A5 (https=
JP2021513368A (ja
Inventor
ワン，チェン－イ
ロウ，ライオネル・ジエンロン
ゴー，アンジェリナ
リー，サンディ・ウェン－シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2021513368A publication Critical patent/JP2021513368A/ja
Publication of JP2021513368A5 publication Critical patent/JP2021513368A5/ja
Priority to JP2023200834A priority Critical patent/JP7755635B2/ja
Application granted granted Critical
Publication of JP7460551B2 publication Critical patent/JP7460551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020565255A 2018-02-13 2019-02-12 抗ｈｅｒ２抗体 Active JP7460551B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023200834A JP7755635B2 (ja) 2018-02-13 2023-11-28 抗ｈｅｒ２抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201801219VA SG10201801219VA (en) 2018-02-13 2018-02-13 Anti-HER2 Antibodies
SG10201801219V 2018-02-13
PCT/SG2019/050077 WO2019160501A1 (en) 2018-02-13 2019-02-12 Anti-her2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023200834A Division JP7755635B2 (ja) 2018-02-13 2023-11-28 抗ｈｅｒ２抗体

Publications (3)

Publication Number Publication Date
JP2021513368A JP2021513368A (ja) 2021-05-27
JP2021513368A5 JP2021513368A5 (https=) 2022-02-22
JP7460551B2 true JP7460551B2 (ja) 2024-04-02

Family

ID=67621044

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565255A Active JP7460551B2 (ja) 2018-02-13 2019-02-12 抗ｈｅｒ２抗体
JP2023200834A Active JP7755635B2 (ja) 2018-02-13 2023-11-28 抗ｈｅｒ２抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023200834A Active JP7755635B2 (ja) 2018-02-13 2023-11-28 抗ｈｅｒ２抗体

Country Status (6)

Country Link
US (1) US11945877B2 (https=)
EP (1) EP3752536A4 (https=)
JP (2) JP7460551B2 (https=)
CN (1) CN112262156B (https=)
SG (2) SG10201801219VA (https=)
WO (1) WO2019160501A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
EP4153635A4 (en) * 2020-05-22 2024-06-26 GC Cell Corporation ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
EP3915576A1 (en) * 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
CN118574646A (zh) * 2022-01-19 2024-08-30 上海优替济生生物医药有限公司 环状rna及其用途
WO2023150544A1 (en) * 2022-02-01 2023-08-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Simplified method of preparing cells for patient administration
US20250222029A1 (en) * 2022-04-08 2025-07-10 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
US20250228943A1 (en) 2022-04-08 2025-07-17 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof
CN114805584B (zh) * 2022-06-30 2022-09-09 上海优替济生生物医药有限公司 抗原结合蛋白及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831987A (zh) 2015-12-04 2017-06-13 浙江大学 一种抗人her2抗体及其编码基因和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
KR20060079258A (ko) 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2009055074A2 (en) * 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
US20150366955A9 (en) 2009-11-11 2015-12-24 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
EP2370103B1 (en) 2008-11-28 2016-03-23 Novartis AG Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US9975960B2 (en) * 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
ES2806776T3 (es) * 2014-06-18 2021-02-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Células NK-92 que expresan CAR como agentes terapéuticos celulares
AU2015277100A1 (en) 2014-06-20 2017-02-02 Abgenomics International Inc. HER2 antibody-drug conjugates
KR101608301B1 (ko) * 2014-08-22 2016-04-12 앱클론(주) Her2에 특이적으로 결합하는 항체
WO2016135239A1 (en) * 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2
JP2018510652A (ja) 2015-03-18 2018-04-19 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Ｈｅｒ２／ｅｒｂｂ２キメラ抗原受容体
KR20180083874A (ko) 2015-11-04 2018-07-23 사울 제이. 프라이스맨 Her2를 표적화하는 키메라 항원 수용체
EP3241847A1 (en) * 2016-05-06 2017-11-08 MAB Discovery GmbH Her-2 binding antibodies
CA3060573A1 (en) * 2017-04-21 2018-10-25 Baylor College Of Medicine Oncolytic virotherapy and immunotherapy
CN107488636A (zh) * 2017-09-30 2017-12-19 山东兴瑞生物科技有限公司 一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831987A (zh) 2015-12-04 2017-06-13 浙江大学 一种抗人her2抗体及其编码基因和应用

Also Published As

Publication number Publication date
CN112262156A (zh) 2021-01-22
WO2019160501A1 (en) 2019-08-22
EP3752536A1 (en) 2020-12-23
US20210139605A1 (en) 2021-05-13
SG11202007735TA (en) 2020-09-29
EP3752536A4 (en) 2022-05-11
JP2024028777A (ja) 2024-03-05
JP7755635B2 (ja) 2025-10-16
CN112262156B (zh) 2024-07-05
JP2021513368A (ja) 2021-05-27
SG10201801219VA (en) 2019-09-27
US11945877B2 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
JP7755635B2 (ja) 抗ｈｅｒ２抗体
US12472252B2 (en) Anti-PD-L1 antibodies
US11142574B2 (en) Anti-TIM-3 antibodies
JP7603738B2 (ja) Ｉｌ２ｒベータ／共通ガンマ鎖抗体
JP6650537B2 (ja) 抗ｃｔｌａ−４抗体
US10435466B2 (en) Anti-TIM-3 antibodies
US20190040136A1 (en) Anti-lag-3 antibodies
CN110770252A (zh) 抗p53抗体
JP2020509745A (ja) ｐ５３−ＭＨＣクラスＩ複合体に結合するＴ細胞受容体様抗体
HK40000388A (en) Anti-ctla-4 antibodies
HK1246324B (en) Anti-pd-l1 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240321

R150 Certificate of patent or registration of utility model

Ref document number: 7460551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150